Thanks to continued commitment to innovation ever since its creation, Medtech is a major player in the French market for surgical robotics today.

A Story of Innovation


Thanks to continued commitment to innovation ever since its creation, Medtech is a major player in the French market for surgical robotics today.

Following the sale of Medtech’s initial orthopedic surgical robot BRIGIT®'s patent portfolio, Medtech created ROSA® Brain, its first neurosurgical robot. ROSA® quickly received CE marking and FDA approval, allowing it to be sold for clinical use both in Europe and the United States.

Since 2012, encouraged by the success of ROSA® Brain, Medtech has continued to innovate with a new R&D project pertaining to spinal surgery. In cooperation with the Languedoc-Roussillon regional council and OSEO, Medtech is striving to meet and exceed the needs of neurosurgeons in this complex area of robotic technology.

ROSA® Spine, the new robotic assistant for spine surgery, obtained CE marking in July 2014 and is currently being adopted throughout Europe. Following the CE marking, the first intervention with ROSA® Spine was performed in November 2014 and its 100th spine operation in May 2016. The ROSA® Spine device received FDA clearance in January 2016.

 

Corporate culture
Medtech began with and still maintains a strong culture of integrity in full compliance with its rules for governance. The management team pays particular attention to the fact that Medtech’s approach to its customers, employees, shareholders and the general medical community is one of complete honesty and respect.